Hooked by the science, Arie Belldegrun joins a group of influentials who believe Dewpoint may have the key to the next big thing in biotech
Amir Nashat knew he had years of preclinical work to do when he talked to me at the beginning of 2019 about Dewpoint Therapeutics and its rare focus on the role bimolecular condensates could play in crafting a wide-ranging pipeline of therapeutics.
And he and his growing transatlantic team of about 70 still have considerable work ahead. Only now he can count Arie Belldegrun, ARCH Venture Partners and a wider circle of influential backers to go the next leg of the journey — now funded through to the point that they can start to get the first look at what their drugs can do in humans.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 163,300+ biopharma pros reading Endpoints daily — and it's free.